Compare NWPX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | FTRE |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.3M | 829.3M |
| IPO Year | 1996 | 2023 |
| Metric | NWPX | FTRE |
|---|---|---|
| Price | $79.30 | $9.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $70.00 | $15.39 |
| AVG Volume (30 Days) | 89.3K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.71 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | $526,003,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $4.48 | $3.01 |
| P/E Ratio | $22.38 | ★ N/A |
| Revenue Growth | ★ 6.79 | 1.00 |
| 52 Week Low | $36.99 | $3.97 |
| 52 Week High | $83.12 | $18.67 |
| Indicator | NWPX | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 42.51 |
| Support Level | $70.24 | $8.85 |
| Resistance Level | $83.12 | $11.22 |
| Average True Range (ATR) | 2.76 | 0.62 |
| MACD | 0.42 | 0.16 |
| Stochastic Oscillator | 84.40 | 53.29 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.